Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT-ENRICH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02540083
Recruitment Status : Terminated (Sponsor has obtained sufficient case load prematurely.)
First Posted : September 3, 2015
Results First Posted : February 5, 2019
Last Update Posted : February 5, 2019
Sponsor:
Information provided by (Responsible Party):
GE Healthcare

Brief Summary:
The aim of this recruitment plan (ADAPT-Enrich) is to collect image and technical data on both digital breast tomosynthesis (DBT) and full-field digital mammography (FFDM), along with other subject data including histology results from biopsy specimen examination and cancer classification data from initially asymptomatic women referred for clinically indicated breast biopsy based on suspicious DBT screening breast imaging results. These data will be included in a subsequent and prospectively planned pooled analysis described in a separate protocol (ADAPT-BIE) examining superiority of DBT to FFDM for breast cancer diagnosis and other performance measures.

Condition or disease Intervention/treatment Phase
Breast Cancer Tumors, Breast Device: DBT and FFDM Not Applicable

Detailed Description:
ADAPT-ENRICH will supplement an on-going program (ADAPT) which consists of 2 additional recruitment plans (ADAPT-SCR and ADAPT-BX) followed by an off-line read of the images and data collected (ADAPT-BIE). This study involves the comparison of two devices that can identify abnormalities in routine breast screening and diagnostic mammography. Mammography is usually done with full-field digital mammography (FFDM), which takes flat, two-dimensional X-ray images of the breast. Doctors use the two-dimensional images to look for cancers and other abnormal tissue. The purpose of this study is to learn more about the accuracy of full-field digital mammography devices and a new mammography device called digital breast tomosynthesis (DBT). DBT is similar to full-field digital mammography, but can also move around the breast to get X-ray images from different angles, which provides a three-dimensional view that doctors can use to look for cancers and abnormal tissue. Subjects will be recruited from an initially asymptomatic population that have been referred for clinically indicated breast biopsy based on suspicious DBT screening breast imaging results. Subjects will undergo a DBT mammogram prior to biopsy. If FFDM was not performed within 30 days, subjects will also undergo FFDM prior to biopsy. Results of biopsy(ies) and histopathology, including lesion characteristics, will be recorded and considered as truth if positive for cancer status. Subjects with negative or benign histological findings will be followed for approximately one year (10-16 months) by FFDM and any additional standard of care practice.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography ADAPT-Enrich: Recruitment Plan for Initially Asymptomatic Women Referred for Breast Biopsy After Screening Digital Breast Tomosynthesis Exam
Actual Study Start Date : August 2015
Actual Primary Completion Date : May 30, 2017
Actual Study Completion Date : May 30, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Experimental: DBT and FFDM
Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT).
Device: DBT and FFDM
Subjects underwent FFDM breast imaging followed by DBT breast imaging
Other Names:
  • Digital Breast Tomosynthesis (3D breast imaging) DBT
  • Full-Field Digital Mammography (2D breast imaging) FFDM




Primary Outcome Measures :
  1. Number of Participants With DBT, FFDM and Biopsy Specimens Collected [ Time Frame: Approximately 8 weeks ]
    For each participant, obtain image data using two methods (DBT and FFDM) and obtain histology results of biopsy specimens from women referred for biopsy.


Secondary Outcome Measures :
  1. Lesion Type Observed by FFDM Imaging [ Time Frame: Approximately 8 weeks ]
    Lesions were characterized based on findings identified during image evaluations performed by qualified readers.

  2. Lesion Type Observed by DBT Imaging [ Time Frame: Approximately 8 weeks ]
    Lesions were characterized based on findings identified during image evaluations performed by qualified researchers.

  3. Lesion Size as Observed by FFDM [ Time Frame: Approximately 8 weeks ]
    Length of Lesions (measured in mm) when images were collected using FFDM.

  4. Lesion Size as Observed by DBT [ Time Frame: Approximately 8 weeks ]
    Length of lesions (measured in mm) when images were collected using DBT.

  5. Biopsy Finding of Lesions [ Time Frame: Approximately 8 weeks ]
    Describes histologic cancer and non-cancer findings of lesion biopsy.


Other Outcome Measures:
  1. Safety - Device Related Malfunctions [ Time Frame: Approximately 8 weeks ]
    Number of device-related malfunctions by imaging modality.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women aged 30 years or older (≥30 years old);
  • Initially asymptomatic women who underwent routine bilateral screening with Digital Breast Tomosynthesis (DBT), followed by diagnostic work-up showing one or more abnormalities and referred for breast biopsy;
  • Are able and willing to comply with study procedures;
  • Have signed and dated the informed consent form;
  • Documented as non-pregnant based on the investigator's medical judgment and in consideration of local clinical practice standards for evidence of non-pregnancy.

Exclusion Criteria:

  • Have been previously included in this study , ADAPT-SCR recruitment plan or ADAPT-BX recruitment plan;
  • Have undergone diagnostic or surgical intervention(s) or procedure(s) on either breast, including mastectomy and cytopunction, before study-related imaging;
  • Have breasts too large to be adequately positioned on 24 x 31 centimeter (cm) DBT or FFDM digital receptor without anatomical cut-off during a DBT or FFDM examination;
  • Have participated in (within the prior 30 days) another trial of an investigational product expected to interfere with study procedures or outcomes;
  • Have breast implant(s);
  • Have reconstructed breast(s).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02540083


Locations
Layout table for location information
United States, North Carolina
Carolina Breast Imaging Specialists
Greenville, North Carolina, United States, 27834
United States, South Dakota
Avera Breast Center
Sioux Falls, South Dakota, United States, 57105
Sponsors and Collaborators
GE Healthcare
  Study Documents (Full-Text)

Documents provided by GE Healthcare:

Layout table for additonal information
Responsible Party: GE Healthcare
ClinicalTrials.gov Identifier: NCT02540083     History of Changes
Other Study ID Numbers: 124.03-2015-GES-0001
First Posted: September 3, 2015    Key Record Dates
Results First Posted: February 5, 2019
Last Update Posted: February 5, 2019
Last Verified: February 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases